Brief: Outlook Therapeutics Announces Preliminary Topline Results Of Norse Eight Clinical Trial
27/11/2024 12:00
Nov 27 (Reuters) - Outlook Therapeutics Inc OTLK.O :
* OUTLOOK THERAPEUTICS® ANNOUNCES PRELIMINARY TOPLINE
RESULTS OF
NORSE EIGHT CLINICAL TRIAL
* OUTLOOK THERAPEUTICS INC -ANTICIPATE RESUBMISSION OF BLA
IN
CALENDAR Q1 2025
* OUTLOOK THERAPEUTICS INC - ONS-5010 DID NOT MEET
NON-INFERIORITY
ENDPOINT IN NORSE EIGHT TRIAL
* OUTLOOK THERAPEUTICS INC - FINAL EFFICACY DATA EXPECTED IN
JANUARY 2025
Source text: ID:nGNX8RHkkB
Further company coverage: OTLK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Outlook Therapeutics
See all newsBrief: Outlook Therapeutics Appoints Kevin Lundquist As Chief Financial Officer As It Prepares For U.S. Commercial Launch Of Lytenava™
Outlook Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Outlook Therapeutics Q3 net loss narrows slightly as costs drop
U.S. STOCKS ON THE MOVE-Tapestry, Cisco, Sandisk
U.S. STOCKS ON THE MOVE-EnerSys, Netflix, Salesforce